“Plus Therapeutics’ commitment to revolutionizing cancer treatment extends beyond this latest award. With $23 million in active awards support, the company is at the forefront of targeted radiotherapeutic research. Moreover, ongoing trials, including ReSPECT-GBM for recurrent glioblastoma and ReSPECT-LM for leptomeningeal metastases, underscore the breadth and depth of Plus Therapeutics’ research endeavors. ” – Stock Region Research (https://bit.ly/4b4OBXG)
Recent DoD Award PR: https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-receives-3-million-award-recommendation-united
Recent Comments